NTRA241220P185000
- 0.00
- 0.000.00%
Natera Newsroom
When Will Natera, Inc. (NASDAQ:NTRA) Breakeven?
Court Grants Natera's Request to Include Additional Patent in Its Lawsuit Against NeoGenomics
TD Cowen Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $195
Express News | Natera Inc : TD Cowen Raises Target Price to $195 From $175
Express News | Natera Inc : Guggenheim Raises Target Price to $170 From $165
Insider Sale: EXECUTIVE CHAIRMAN of $NTRA (NTRA) Sells 5,300 Shares
Natera(NTRA.US) Officer Sells US$26.52 Million in Common Stock
Express News | Form 144 | Natera(NTRA.US) Director Proposes to Sell 26.63 Million in Common Stocks
Natera Is Maintained at Overweight by JP Morgan
Natera Analyst Ratings
J.P. Morgan Maintains Natera(NTRA.US) With Buy Rating, Raises Target Price to $200
Natera Announces Enrollment Of First Patients In SAGITTARIUS A Randomized Phase III Clinical Trial In Colon Cancer; ~700-900 Patients Expected To Be Enrolled Across More Than 20 Sites
Express News | Natera Inc - 700-900 Patients Expected to Be Enrolled in Trial
Express News | Natera Announces Enrollment of First Patients in Sagittarius: A Randomized, Phase III Clinical Trial in Colon Cancer
Natera Announces Enrollment of First Patients in SAGITTARIUS: a Randomized, Phase III Clinical Trial in Colon Cancer
Express News | Natera Inc : Leerink Partners Raises Target Price to $200 From $185
Natera and MyOme Announce Launch of IPRS for Breast Cancer Risk Assessment
Natera Aligns Executive Chairman's Pay With Performance
Natera(NTRA.US) Director Sells US$14.79 Million in Common Stock
Natera Insider Sold Shares Worth $14,793,563, According to a Recent SEC Filing